CA2153797A1 - Combination of a soluble complement receptor-1(scri) and an amidinophenyl or amidinonaphthyl-ester for treating inflammation - Google Patents

Combination of a soluble complement receptor-1(scri) and an amidinophenyl or amidinonaphthyl-ester for treating inflammation

Info

Publication number
CA2153797A1
CA2153797A1 CA002153797A CA2153797A CA2153797A1 CA 2153797 A1 CA2153797 A1 CA 2153797A1 CA 002153797 A CA002153797 A CA 002153797A CA 2153797 A CA2153797 A CA 2153797A CA 2153797 A1 CA2153797 A1 CA 2153797A1
Authority
CA
Canada
Prior art keywords
apan
brl55730
amidinophenyl
soluble
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002153797A
Other languages
English (en)
French (fr)
Inventor
Danuta Ewa Irena Mossakowska
Richard Anthony Godwin Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2153797A1 publication Critical patent/CA2153797A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002153797A 1993-01-22 1994-01-21 Combination of a soluble complement receptor-1(scri) and an amidinophenyl or amidinonaphthyl-ester for treating inflammation Abandoned CA2153797A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939301289A GB9301289D0 (en) 1993-01-22 1993-01-22 Novel composition
GB9301289.6 1993-01-22

Publications (1)

Publication Number Publication Date
CA2153797A1 true CA2153797A1 (en) 1994-08-04

Family

ID=10729169

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002153797A Abandoned CA2153797A1 (en) 1993-01-22 1994-01-21 Combination of a soluble complement receptor-1(scri) and an amidinophenyl or amidinonaphthyl-ester for treating inflammation

Country Status (10)

Country Link
EP (1) EP0680332A1 (enExample)
JP (1) JPH08505867A (enExample)
CN (1) CN1118141A (enExample)
AU (1) AU5863694A (enExample)
CA (1) CA2153797A1 (enExample)
GB (1) GB9301289D0 (enExample)
NZ (1) NZ259737A (enExample)
TW (1) TW241203B (enExample)
WO (1) WO1994016719A1 (enExample)
ZA (1) ZA94398B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69431194T2 (de) * 1993-10-21 2002-12-12 G.D. Searle & Co., Chicago Amidino-derivate nützlich als no synthase-hemmer
GB9604518D0 (en) * 1996-03-02 1996-05-01 Smithkline Beecham Plc Novel compounds
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
JP4897690B2 (ja) * 2004-10-12 2012-03-14 ジェネンテック， インコーポレイテッド 補体関連障害の予防および処置のためのＣＲＩｇポリペプチド
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ191320A (en) * 1978-09-07 1982-09-14 Beecham Group Ltd In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions
DE3207033C2 (de) * 1981-02-27 1984-09-13 Torii & Co., Ltd., Tokyo Amidinverbindungen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Mittel
JPS57179147A (en) * 1981-04-28 1982-11-04 Torii Yakuhin Kk Amidine derivative
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
EP0560929A1 (en) * 1990-12-06 1993-09-22 T Cell Sciences, Inc. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity

Also Published As

Publication number Publication date
WO1994016719A1 (en) 1994-08-04
AU5863694A (en) 1994-08-15
TW241203B (enExample) 1995-02-21
EP0680332A1 (en) 1995-11-08
GB9301289D0 (en) 1993-03-17
NZ259737A (en) 1997-04-24
CN1118141A (zh) 1996-03-06
ZA94398B (en) 1994-11-15
JPH08505867A (ja) 1996-06-25

Similar Documents

Publication Publication Date Title
KR101755058B1 (ko) 특정 ｈｃｖ ｎｓ５ａ 억제제 및 ｈｃｖ ｎｓ３ 프로테아제 억제제의 조합물
HU219445B (hu) Interleukin-1 inhibitorokat tartalmazó, stabil gyógyszerkészítmények és eljárás előállításukra
TWI289454B (en) Pegylated interferon alfa combination HIV therapy
US9150638B2 (en) Factor XII inhibitors for treating interstitial lung disease
US20080255038A1 (en) Pharmaceutical compositions
ES2774296T3 (es) Terapias de combinación para tratar cánceres quimiorresistentes
JPH10503177A (ja) 酵素インヒビターとしてのアルギニン模倣物を含む３−アミノ−２−オキソ−１−ピペリジン酢酸誘導体
CN105579433A (zh) 用于预防和治疗炎症的Cryopyrin抑制剂
JP2021519764A (ja) 線維性疾患を処置する方法
ES2307593T3 (es) Antagonistas del receptor a2a de adenosina para el tratamiento y la prevencion de la fibrosis hepatica, la cirrosis y la esteatosis hepatica.
CN113768870B (zh) 含青蒿琥酯的组合物及其应用
CA2153797A1 (en) Combination of a soluble complement receptor-1(scri) and an amidinophenyl or amidinonaphthyl-ester for treating inflammation
ES2547726T3 (es) Nueva enzima altamente funcional que tiene especificidad de sustrato modificada
US9359419B2 (en) Treatment of vascular complications of diabetes
WO2009151714A2 (en) Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions
CA2557615A1 (en) Treatment of haemorrhagic shock using complement 5a receptor inhibitors
JPH03215426A (ja) 血糖上昇抑制剤
US20120020923A1 (en) Method of treating viral diseases with combinations of TPO receptor agonist and anti-viral agents
JP2023523568A (ja) ＡｃｔＲＩＩＢリガンドトラップ及びフェドラチニブを使用して貧血を治療するための方法
US20090074721A1 (en) Methods for treating viral infection with oral or injectibel drug solution
JPWO2003024445A1 (ja) 抗血栓薬とピラゾロン誘導体との組み合わせ薬剤
Enkhbaatar et al. Recombinant tissue factor pathway inhibitor prevents lipopolysaccharide-induced systemic hypotension in rats by inhibiting excessive production of nitric oxide
KR20090120350A (ko) 니코틴산 아데닌 디뉴클레오티드 인산 또는 그 유도체의 제2형 당뇨병 치료제로서의 용도
JPH03133927A (ja) 虚血後の心筋機能障害の改善剤
JP4287523B2 (ja) 抗腫瘍剤

Legal Events

Date Code Title Description
FZDE Dead